glp level 1 GLP-1 Agonists For Obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH A Comprehensive Review of the

Unlike the SUSTAIN-6 study, this study excluded any patients who had pre-existing proliferative diabetic retinopathy (PDR) prior to initiation of tirzepatide and matched patients with their baseline level of DR or DME

Doctors typically prescribe it to help some people with type 2 diabetes

This precision approach reduces trial-and-error dosing and increases the likelihood of sustained weight loss success

Conclusions Our results indicate that weight loss through GLP-based therapies is not associated with prolithogenic changes in 24-hour urine chemistry in patients with nephrolithiasis, unlike what happens with other weight loss modalities

Leptin and leptin resistance in obesity: current evidence, mechanisms and future directions

Gastrointestinal adverse effects represent the most frequently reported side effects of semaglutide therapy, with rates varying by dose, formulation, and indication